Search results for " Cardiovascular Disease"

showing 10 items of 179 documents

Mediterranean diet impact on cardiovascular diseases: a narrative review

2017

Cardiovascular disease (CVD) accounts for more than 17 million deaths per year worldwide. It has been estimated that the influence of lifestyle on CVD mortality amounts to 13.7% for smoking, 13.2% for poor diet, and 12% for inactive lifestyle. These results deeply impact both the healthy status of individuals and their skills in working. The impact of CVD on productivity loss accounts for the 24% in total costs for CVD management. Mediterranean diet (MedD) can positively impact on natural history of CVD. It is characterized by a relatively high consumption of inexpensive and genuine food such as cereals, vegetables, legumes, nuts, fish, fresh fruits, and olive oil as the principal source of…

lifestyleMediterranean dietinactive lifestyleDisease030204 cardiovascular system & hematologyDiet MediterraneanSudden cardiac deathCoronary artery disease03 medical and health sciencescardiovascular diseases lifestyle Mediterranean diet preventive cardiology vascular diseasesVascular Stiffness0302 clinical medicinecardiovascular diseaseEnvironmental healthMediterranean dietmedicineHumansHealthy Lifestyle030212 general & internal medicineMediterranean diet impact on cardiovascular diseasesRandomized Controlled Trials as TopicalimentationTraditional medicinebusiness.industrycardiovascular disease (CVD)preventive cardiologyfood and beveragesvascular diseasemediterranean dietGeneral Medicinemedicine.diseaseNatural historycardiovascular diseases; lifestyle; Mediterranean diet; preventive cardiology; vascular diseases; Cardiology and Cardiovascular MedicineCardiovascular Diseasesmediterranean diet cardiovascular diseaseHeart failureArterial stiffnesscardiovascular disease (CVD); inactive lifestyle; alimentationvascular diseasesNarrative reviewbusinessCardiology and Cardiovascular Medicine
researchProduct

Magnesium and Health

2019

Magnesium (Mg) is the second most abundant cation after potassium in the intracellular compartment and has a critical role in modulating a large variety of cellular activities and metabolic pathways. Mg is cofactor in over 300 enzymatic reactions including all reactions that involve ATP utilization and transfer [1,2]. Over the past decades, the clinical relevance of Mg and its impact on health has been documented. In the human body, around 24 grams (1 mole) of Mg are present. Less than 1% of total Mg is in the serum; normal serum Mg concentrations range between 0.75-0.95 mmol/L (1.7-2.5 mg/dL or 1.5-1.9 meq/L). In healthy adults, daily Mg requirement is around 300-400 mg (5 to 6 mg/kg/day) …

magnesium chronic disease multimorbidigy aging diabetes hypertension cardiovascular diseaseSettore MED/09 - Medicina InternachemistryTraditional medicineMagnesiumbusiness.industrychemistry.chemical_elementMedicineOmicsbusiness
researchProduct

Association Between Gait Speed With Mortality, Cardiovascular Disease and Cancer:A Systematic Review and Meta-analysis of Prospective Cohort Studies

2018

Objectives: Slow gait speed may be associated with premature mortality, cardiovascular disease (CVD), and cancer, although a comprehensive meta-analysis is lacking. In this systematic review and meta-analysis, we explored potential associations between gait speed and mortality, incident CVD, and cancer. Design: A systematic search in major databases was undertaken from inception until March 15, 2018 for prospective cohort studies reporting data on gait speed and mortality, incident CVD, and cancer. Setting and Participants: All available. Measures: The adjusted hazard ratios (HRs) and 95% confidence intervals (CIs), based on the model with the maximum number of covariates for each study bet…

medicine.medical_specialty*meta-analysisSocio-culturaleDisease030204 cardiovascular system & hematologyRisk AssessmentGait speed mortality cardiovascular disease cancer meta-analysisGait speed*mortality03 medical and health sciences0302 clinical medicine*cancercardiovascular diseaseNeoplasmsInternal medicine*Gait speedHumansMedicinecancer030212 general & internal medicinecancer; cardiovascular disease; Gait speed; meta-analysis; mortality; Nursing (all)2901 Nursing (miscellaneous); Health PolicyProspective cohort studyGeneral NursingNursing (all)2901 Nursing (miscellaneous)business.industryHealth PolicyHazard ratioConfoundingCancer*cardiovascular diseaseGeneral MedicinePublication biasmedicine.diseasemortalityConfidence intervalWalking Speedmeta-analysisCardiovascular DiseasesMeta-analysisGeriatrics and Gerontologybusiness
researchProduct

Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children.

2018

Dyslipdiemia can manifest at a young age, and it is a risk factor for atherosclerotic cardiovascular disease (ASCVD), the principal cause of mortality in developed nations. Therefore, treating it a...

medicine.medical_specialtyAdolescentFamilial hypercholesterolemiastatins03 medical and health sciences0302 clinical medicineEzetimibechildrenmedicinePharmacology (medical)Risk factorIntensive care medicinePharmacologyfamilial hypercholesterolemiaAtherosclerotic cardiovascular diseasebusiness.industryfungidyslipidemiafood and beveragesGeneral Medicinemedicine.diseaseYoung age030220 oncology & carcinogenesisbusinessDeveloped country030217 neurology & neurosurgeryDyslipidemiamedicine.drugezetimibeExpert opinion on pharmacotherapy
researchProduct

Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acqui…

2019

Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and improves the efficacy of therapy, but can increase the risk of severe side effects. Due to these premises it has always raised doubts and perplexities in the clinics. We now report the data of the "FEIBA® on acquired haemophilia A Italian Registry (FAIR Registry)", a retrospective-prospective study that included 56 patients. This is the first study that assessed the clinical response of the combination of aPCC and antifibrinolytic agents in patients with acquired haemophilia A. A total of 101 acute bleeds…

medicine.medical_specialtyAntifibrinolyticmedicine.drug_classHemorrhage030204 cardiovascular system & hematologyHemophilia APremises03 medical and health sciences0302 clinical medicineDrug TherapyThromboembolismAntifibrinolytic agentInternal medicineActivated prothrombin complex concentrateAcquired haemophiliaThromboembolic riskHumansMedicineIn patientRegistries030212 general & internal medicineAcquired haemophilia AHematologybusiness.industryHematologyAcquired haemophilia A; Activated prothrombin complex concentrate; Antifibrinolytics; Thromboembolic risk; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiovascular Diseases; Drug Therapy Combination; Hemophilia A; Hemorrhage; Humans; Registries; ThromboembolismAntifibrinolytic AgentsBlood Coagulation FactorsClinical trialTolerabilityCardiovascular DiseasesCombinationAntifibrinolyticDrug Therapy CombinationAntifibrinolyticsCardiology and Cardiovascular Medicinebusiness
researchProduct

Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome

2011

The metabolic syndrome (MetS) is common, and its associated risk burdens of diabetes and cardiovascular disease (CVD) are a major public health problem. The hypothesis that main constituent parameters of the MetS share common pathophysiologic mechanisms provides a conceptual framework for the future research. Exercise and weight loss can prevent insulin resistance and reduce the risk of diseases associated with the MetS. Interrupting intracellular and extracellular reactive oxygen species (ROS) overproduction could also contribute to normalizing the activation of metabolic pathways leading to the onset of diabetes, endothelial dysfunction, and cardiovascular (CV) complications. On the other…

medicine.medical_specialtyAntioxidantmedicine.medical_treatmentHyperlipidemiasDiseaseBioinformaticsmetabolic syndromeAntioxidants03 medical and health sciences0302 clinical medicineInsulin resistancecardiovascular diseaseWeight lossinsulin resistanceDiabetes mellitusInternal medicineDrug Discoverymedicineoxidative stressHumansObesityEndothelial dysfunctionantioxidants cardiovascular disease insulin resistance metabolic syndrome oxidative stress reactive oxygen species.Dyslipidemias030304 developmental biologyreactive oxygen speciesInflammationMetabolic SyndromePharmacology0303 health sciencesbusiness.industryThrombosismedicine.disease3. Good healthFatty LiverClinical trialOxidative StressantioxidantsEndocrinologyObesity Abdominal030220 oncology & carcinogenesisHypertensionInsulin ResistanceMetabolic syndromemedicine.symptombusinessSignal TransductionCurrent Pharmaceutical Design
researchProduct

Osteoarthritis and mortality: a prospective cohort study and systematic review with meta-analysis

2016

Objectives: Osteoarthritis (OA) is a leading cause of disability, but the relationship with premature mortality remains uncertain. We aimed to investigate the relationship between OA and mortality from any cause and from cardiovascular disease (CVD).\ud \ud Methods: Electronic literature databases searches were conducted to identify prospective studies comparing mortality in a sample of people with and without OA. Risk of all-cause and CVD mortality were summarized using adjusted hazard ratios (HRs) for joint specific (hand, hip, and knee) and joint non-specific OA. New data from the Progetto Veneto Anziani (PRO.V.A.) study were also included. Results: From the PRO.V.A. study (N 1⁄4 2927), …

medicine.medical_specialtyCardiovascular disease; Mortality; Osteoarthritis; Rheumatology; Anesthesiology and Pain MedicineOsteoarthritisDiseaseComorbidity03 medical and health sciences0302 clinical medicineRheumatologycardiovascular diseaseRisk FactorsInternal medicineOsteoarthritismedicineHumans030212 general & internal medicineProspective StudiesMortalityProspective cohort study030203 arthritis & rheumatologybusiness.industryHazard ratioOsteoarthritis Mortality Cardiovascular diseasemedicine.diseaseCardiovascular diseaseR1ComorbiditymortalityRheumatologyosteoarthritisIncreased riskAnesthesiology and Pain MedicineCardiovascular DiseasesMeta-analysisPhysical therapybusinessCardiovascular disease; Mortality; Osteoarthritis
researchProduct

Clinical indications for cardiac computed tomography. From the Working Group of the Cardiac Radiology Section of the Italian Society of Medical Radio…

2012

"\"La tomografia computerizzata del cuore (CCT) è diventata uno strumento efficace in differenti contesti clinici. Lo sviluppo della tecnologia ha portato ad una progressiva espansione delle indicazioni con una concomitante riduzione della dose di radiazioni necessaria per l’esecuzione dell’indagine. Ancora oggi sono pochi i documenti delle maggiori società scientifiche internazionali che si esprimono sulle effettive modalità di utilizzo e sulle indicazioni cliniche della CCT; in particolare mancano delle linee guida complete. Questo documento rispecchia la visione del gruppo di lavoro della Sezione di Cardio-Radiologia della Società Italiana di Radiologia Medica in merito alle indicazioni …

medicine.medical_specialtyConsensuslinee guidagenetic structuresCardiac computed tomographyClinical indicationscardiac CTGuidelinesRadiation DosageComputed tomography coronary angiographycctCCT; Clinical indications; Computed tomography coronary angiography; Consensus; CTCA; Guidelines; Cardiovascular Diseases; Humans; Italy; Radiation Dosage; Tomography X-Ray ComputedmedicinectcaHumansRadiology Nuclear Medicine and imagingMedical physicsguidelinesTomographyNeuroradiologymedicine.diagnostic_testbusiness.industryRadiation doseCTCAInterventional radiologyGeneral Medicineindicazioni clinichecomputed tomography coronary angiographyctca; guidelines; consensus; clinical indications; computed tomography coronary angiography; cctAngiografia coronarica a tomografia computerizzataconsensoeye diseasesAngiografia coronarica a tomografia computerizzata linee guida consenso indicazioni cliniche; computed tomography coronary angiography guidelines consensus clinical indicationsCCTX-Ray ComputedItalyconsensusCardiovascular DiseasesClinical indicationsense organsRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessTomography X-Ray Computedclinical indicationsLa Radiologia medica
researchProduct

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C

2021

INTRODUCTION: In the last years the Hepatitis C virus (HCV) infection was a relevant public health problem due to the large number of affected people worldwide and the impact on hepatic and extrahepatic complications. The availability of direct-acting antivirals (DAAs) and the very high rate of sustained virological response (SVR) after treatment has radically changed the course of HCV chronic infection. EVIDENCE ACQUISITION: We searched PubMed for articles published between January 1, 1995, through December 31, 2020, in English language. EVIDENCE SYNTHESIS: Robust evidence showed a close link between HCV infection and development of cardiovascular disease (CVD), as result of the atherogeni…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHepatitis C virusMEDLINEHepacivirusDiseaseDIRECT ACTING ANTIVIRALSmedicine.disease_causeAntiviral AgentsVirusInternal medicineInternal MedicinemedicineHumansHepatitis chronic Cardiovascular diseases Antiviral agentsIn patientbusiness.industryPublic healthGastroenterologyvirus diseasesHepatitis C Chronicdigestive system diseasesChronic infectionCardiovascular DiseasesPersistent Infectionbusiness
researchProduct